Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07148128 · ClinicalTrials.gov registry record · Phase 1
Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.
A Phase 1 study of Advanced Solid Tumors and Advanced or Metastatic KRAS-mutant Tumor in Pancreatic Adenocarcinoma, sponsored by Auricula Biosciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 110
- Enrollment target
- 4
- Study locations
NCT07148128 is a Phase 1 study of Advanced Solid Tumors and Advanced or Metastatic KRAS-mutant Tumor in Pancreatic Adenocarcinoma that is actively recruiting participants, run by Auricula Biosciences. The registered enrollment target is 110 participants, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (44% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT07148128, a Phase 1 study of Advanced Solid Tumors and Advanced or Metastatic KRAS-mutant Tumor in Pancreatic Adenocarcinoma, is actively recruiting participants, sponsored by Auricula Biosciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 110 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a study designed to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of WEF-001 as monotherapy in patients with Advanced KRAS-mutant solid tumours.
Conditions Studied
Interventions
- DRUG WEF-001
Study Locations (4)
Texas
- NEXT Oncology Dallas - Dallas
- Next Oncology, San Antonio - San Antonio
Ontario
- Princess Margareth Cancer Center - Toronto
Oxford
- Oxford University Hospital - Headington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2025-07-28 |
| Est. Completion | 2028-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07148128
The ClinicalTrials.gov registry entry for NCT07148128 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (44% lower). The listed sponsor is Auricula Biosciences, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Advanced Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which WEF-001 is the first listed.
NCT07148128 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Texas, Ontario, Oxford.
Frequently Asked Questions
What is clinical trial NCT07148128 about?
NCT07148128 is a clinical study titled "Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.". This is a study designed to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of WEF-001 as monotherapy in patients with Advanced KRAS-mutant solid tumours.
What is the current status of trial NCT07148128?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 110 participants. The study started on 2025-07-28. Estimated completion is 2028-01.
What conditions does trial NCT07148128 study?
This clinical trial studies the following conditions: Advanced Solid Tumors, Advanced or Metastatic KRAS-mutant Tumor in Pancreatic Adenocarcinoma, Advanced or Metastatic KRAS-mutant Tumor in Colorectal Cancer, Advanced or Metastatic KRAS-mutant Tumor in Non Small Cell Lung Cancer, Advanced or Metastatic KRAS-mutant Tumor.
What interventions are being tested in trial NCT07148128?
The interventions under investigation include: WEF-001 (DRUG).
Who is sponsoring clinical trial NCT07148128?
This trial is sponsored by Auricula Biosciences, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07148128 being conducted?
This trial has 4 study locations across Texas, Ontario, Oxford. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
RECRUITING · Phase 1
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
RECRUITING · Phase 1
-
SNV4818 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Advanced Solid Tumors
All registered trials for this condition
Advanced or Metastatic KRAS-mutant Tumor in Pancreatic Adenocarcinoma
All registered trials for this condition
Texas
All trials with a study site in Texas
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.